167
Participants
Start Date
Not specified
Study Completion Date
March 31, 1998
Sevirumab
Foscarnet sodium
Ganciclovir
SUNY - Buffalo, Erie County Medical Ctr., Buffalo
Univ. of Rochester ACTG CRS, Rochester
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia
Alabama Therapeutics CRS, Birmingham
Case CRS, Cleveland
Cook County Hosp. CORE Ctr., Chicago
Rush Univ. Med. Ctr. ACTG CRS, Chicago
University of Colorado Hospital CRS, Aurora
Queens Med. Ctr., Honolulu
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
Univ. of Miami AIDS CRS, Miami
Univ. of Cincinnati CRS, Cincinnati
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
USC CRS, Los Angeles
Stanford CRS, Stanford
Santa Clara Valley Med. Ctr., San Jose
Massachusetts General Hospital ACTG CRS, Boston
Beth Israel Deaconess - East Campus A0102 CRS, Boston
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston
Washington U CRS, St Louis
Collaborators (1)
Facet Biotech
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH